26 May 2020

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications

Axxam S.p.A. announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs.
01 May 2020

CORONAVIRUS - Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2

A commitment to support the identification of antiviral therapies to treat the severe acute respiratory syndrome COVID-19, caused by the Coronavirus SARS-CoV-2.
19 April 2020

Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

Tranche 3 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system.
15 April 2020

EryDel announces completion of patient enrollment in Phase 3 ATTeST trial the largest clinical study ever conducted in Ataxia Telangiectasia

EryDel SpA announced the completion of patient enrollment of ATTeST, the Phase 3 pivotal trial in Ataxia Telangiectasia . Topline data from the study are expected at the end of 2020.
03 April 2020

ERS Genomics and Axxam announce CRISPR-Cas9 license agreement to enhance discovery services

The application of the CRISPR-Cas9 platform is an important addition to Axxam’s range of innovative approaches for development of highly-customized cell-based assays for relevant target classes and molecular pathways
23 March 2020

CORONAVIRUS - DiaSorin COVID-19 test has received FDA Emergency Use Authorization

DiaSorin Molecular LLC, a division of DiaSorin S.p.A. announced that it has received Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit.


Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341